Report cover image

Global Antiretroviral Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20556752

Description

Summary

According to APO Research, the global Antiretroviral Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Antiretroviral Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Antiretroviral Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Antiretroviral Drug market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Antiretroviral Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Antiretroviral Drug market include Boehringer-Ingelheim, Bristol-Myer Squibb, CIPLA, Gilead Sciences, ViiV Healthcare, AbbVie, Merck and Johnson and Johnson, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Antiretroviral Drug, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Antiretroviral Drug, also provides the value of main regions and countries. Of the upcoming market potential for Antiretroviral Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiretroviral Drug revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Antiretroviral Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Antiretroviral Drug company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Antiretroviral Drug Segment by Company

Boehringer-Ingelheim
Bristol-Myer Squibb
CIPLA
Gilead Sciences
ViiV Healthcare
AbbVie
Merck
Johnson and Johnson
Antiretroviral Drug Segment by Type

Multi-Class Drugs Combination
Protease Inhibitors
NRTI
NNRTI
Other
Antiretroviral Drug Segment by Application

Hospital
Pharmaceutical Companies
Other
Antiretroviral Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Antiretroviral Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Antiretroviral Drug key companies, revenue, market share, and recent developments.
3. To split the Antiretroviral Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Antiretroviral Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Antiretroviral Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Antiretroviral Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiretroviral Drug industry.
Chapter 3: Detailed analysis of Antiretroviral Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Antiretroviral Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Antiretroviral Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Antiretroviral Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Antiretroviral Drug Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Antiretroviral Drug Market Dynamics
2.1 Antiretroviral Drug Industry Trends
2.2 Antiretroviral Drug Industry Drivers
2.3 Antiretroviral Drug Industry Opportunities and Challenges
2.4 Antiretroviral Drug Industry Restraints
3 Antiretroviral Drug Market by Company
3.1 Global Antiretroviral Drug Company Revenue Ranking in 2024
3.2 Global Antiretroviral Drug Revenue by Company (2020-2025)
3.3 Global Antiretroviral Drug Company Ranking (2023-2025)
3.4 Global Antiretroviral Drug Company Manufacturing Base and Headquarters
3.5 Global Antiretroviral Drug Company Product Type and Application
3.6 Global Antiretroviral Drug Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Antiretroviral Drug Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Antiretroviral Drug Market by Type
4.1 Antiretroviral Drug Type Introduction
4.1.1 Multi-Class Drugs Combination
4.1.2 Protease Inhibitors
4.1.3 NRTI
4.1.4 NNRTI
4.1.5 Other
4.2 Global Antiretroviral Drug Sales Value by Type
4.2.1 Global Antiretroviral Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Antiretroviral Drug Sales Value by Type (2020-2031)
4.2.3 Global Antiretroviral Drug Sales Value Share by Type (2020-2031)
5 Antiretroviral Drug Market by Application
5.1 Antiretroviral Drug Application Introduction
5.1.1 Hospital
5.1.2 Pharmaceutical Companies
5.1.3 Other
5.2 Global Antiretroviral Drug Sales Value by Application
5.2.1 Global Antiretroviral Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Antiretroviral Drug Sales Value by Application (2020-2031)
5.2.3 Global Antiretroviral Drug Sales Value Share by Application (2020-2031)
6 Antiretroviral Drug Regional Value Analysis
6.1 Global Antiretroviral Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Antiretroviral Drug Sales Value by Region (2020-2031)
6.2.1 Global Antiretroviral Drug Sales Value by Region: 2020-2025
6.2.2 Global Antiretroviral Drug Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Antiretroviral Drug Sales Value (2020-2031)
6.3.2 North America Antiretroviral Drug Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antiretroviral Drug Sales Value (2020-2031)
6.4.2 Europe Antiretroviral Drug Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Antiretroviral Drug Sales Value (2020-2031)
6.5.2 Asia-Pacific Antiretroviral Drug Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Antiretroviral Drug Sales Value (2020-2031)
6.6.2 South America Antiretroviral Drug Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Antiretroviral Drug Sales Value (2020-2031)
6.7.2 Middle East & Africa Antiretroviral Drug Sales Value Share by Country, 2024 VS 2031
7 Antiretroviral Drug Country-level Value Analysis
7.1 Global Antiretroviral Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Antiretroviral Drug Sales Value by Country (2020-2031)
7.2.1 Global Antiretroviral Drug Sales Value by Country (2020-2025)
7.2.2 Global Antiretroviral Drug Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.3.2 USA Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.4.2 Canada Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.6.2 Germany Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.7.2 France Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.7.3 France Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.9.2 Italy Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.10.2 Spain Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.11.2 Russia Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.14.2 China Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 China Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.15.2 Japan Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.17.2 India Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 India Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.18.2 Australia Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.22.2 Chile Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.24.2 Peru Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.26.2 Israel Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.27.2 UAE Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.29.2 Iran Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Antiretroviral Drug Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Antiretroviral Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Antiretroviral Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Boehringer-Ingelheim
8.1.1 Boehringer-Ingelheim Comapny Information
8.1.2 Boehringer-Ingelheim Business Overview
8.1.3 Boehringer-Ingelheim Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.1.4 Boehringer-Ingelheim Antiretroviral Drug Product Portfolio
8.1.5 Boehringer-Ingelheim Recent Developments
8.2 Bristol-Myer Squibb
8.2.1 Bristol-Myer Squibb Comapny Information
8.2.2 Bristol-Myer Squibb Business Overview
8.2.3 Bristol-Myer Squibb Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.2.4 Bristol-Myer Squibb Antiretroviral Drug Product Portfolio
8.2.5 Bristol-Myer Squibb Recent Developments
8.3 CIPLA
8.3.1 CIPLA Comapny Information
8.3.2 CIPLA Business Overview
8.3.3 CIPLA Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.3.4 CIPLA Antiretroviral Drug Product Portfolio
8.3.5 CIPLA Recent Developments
8.4 Gilead Sciences
8.4.1 Gilead Sciences Comapny Information
8.4.2 Gilead Sciences Business Overview
8.4.3 Gilead Sciences Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.4.4 Gilead Sciences Antiretroviral Drug Product Portfolio
8.4.5 Gilead Sciences Recent Developments
8.5 ViiV Healthcare
8.5.1 ViiV Healthcare Comapny Information
8.5.2 ViiV Healthcare Business Overview
8.5.3 ViiV Healthcare Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.5.4 ViiV Healthcare Antiretroviral Drug Product Portfolio
8.5.5 ViiV Healthcare Recent Developments
8.6 AbbVie
8.6.1 AbbVie Comapny Information
8.6.2 AbbVie Business Overview
8.6.3 AbbVie Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.6.4 AbbVie Antiretroviral Drug Product Portfolio
8.6.5 AbbVie Recent Developments
8.7 Merck
8.7.1 Merck Comapny Information
8.7.2 Merck Business Overview
8.7.3 Merck Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.7.4 Merck Antiretroviral Drug Product Portfolio
8.7.5 Merck Recent Developments
8.8 Johnson and Johnson
8.8.1 Johnson and Johnson Comapny Information
8.8.2 Johnson and Johnson Business Overview
8.8.3 Johnson and Johnson Antiretroviral Drug Revenue and Gross Margin (2020-2025)
8.8.4 Johnson and Johnson Antiretroviral Drug Product Portfolio
8.8.5 Johnson and Johnson Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.